Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group.

N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123.

2.

A prospective study of a long-term follow-up of an observation program for neuroblastoma detected by mass screening.

Tanaka M, Kigasawa H, Kato K, Ijiri R, Nishihira H, Aida N, Ohama Y, Tanaka Y.

Pediatr Blood Cancer. 2010 Apr;54(4):573-8. doi: 10.1002/pbc.22400.

PMID:
20049932
3.

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.

Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, De Bernardi B, Noguera R, Piqueras M, Cañete A, Castel V, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Michon J, Combaret V, Fischer M, Oberthuer A, Ambros PF, Beiske K, Bénard J, Marques B, Rubie H, Kohler J, Pötschger U, Ladenstein R, Hogarty MD, McGrady P, London WB, Laureys G, Speleman F, Vandesompele J.

Lancet Oncol. 2009 Jul;10(7):663-71. doi: 10.1016/S1470-2045(09)70154-8. Epub 2009 Jun 8.

4.

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.

Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, Attiyeh EF, Mosse YP, Kim C, Diskin SJ, Cole KA, Bosse K, Diamond M, Laudenslager M, Winter C, Bradfield JP, Scott RH, Jagannathan J, Garris M, McConville C, London WB, Seeger RC, Grant SF, Li H, Rahman N, Rappaport E, Hakonarson H, Maris JM.

Nat Genet. 2009 Jun;41(6):718-23. doi: 10.1038/ng.374. Epub 2009 May 3.

5.

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG.

J Clin Oncol. 2009 Mar 1;27(7):1007-13. doi: 10.1200/JCO.2007.13.8925. Epub 2009 Jan 26. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1862-3.

6.

Overall genomic pattern is a predictor of outcome in neuroblastoma.

Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, Plantaz D, Rubie H, Valteau-Couanet D, Thomas C, Combaret V, Rousseau R, Eggert A, Michon J, Speleman F, Delattre O.

J Clin Oncol. 2009 Mar 1;27(7):1026-33. doi: 10.1200/JCO.2008.16.0630. Epub 2009 Jan 26.

PMID:
19171713
7.

Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification.

De Bernardi B, Gerrard M, Boni L, Rubie H, Cañete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson AD.

J Clin Oncol. 2009 Mar 1;27(7):1034-40. doi: 10.1200/JCO.2008.17.5877. Epub 2009 Jan 26.

PMID:
19171711
8.

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK; INRG Task Force.

J Clin Oncol. 2009 Jan 10;27(2):289-97. doi: 10.1200/JCO.2008.16.6785. Epub 2008 Dec 1.

9.

Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study.

Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD, Goodman MT, Lynch CF, Schwartz SM, Chen VW, Bernstein L, Gomez SL, Graff JJ, Lin CC, Johnson NJ, Edwards BK.

Cancer Causes Control. 2009 May;20(4):417-35. doi: 10.1007/s10552-008-9256-0. Epub 2008 Nov 12.

10.

Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999.

Linabery AM, Ross JA.

Cancer. 2008 Nov 1;113(9):2575-96. doi: 10.1002/cncr.23866.

11.

Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans.

Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME.

Mol Cancer Ther. 2008 Sep;7(9):3038-46. doi: 10.1158/1535-7163.MCT-08-0248. Epub 2008 Sep 2.

12.

Chromosome 6p22 locus associated with clinically aggressive neuroblastoma.

Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH, Asgharzadeh S, Attiyeh EF, Diskin SJ, Laudenslager M, Winter C, Cole KA, Glessner JT, Kim C, Frackelton EC, Casalunovo T, Eckert AW, Capasso M, Rappaport EF, McConville C, London WB, Seeger RC, Rahman N, Devoto M, Grant SF, Li H, Hakonarson H.

N Engl J Med. 2008 Jun 12;358(24):2585-93. doi: 10.1056/NEJMoa0708698. Epub 2008 May 7.

13.

Neuroblastoma.

Maris JM, Hogarty MD, Bagatell R, Cohn SL.

Lancet. 2007 Jun 23;369(9579):2106-20. Review.

PMID:
17586306
14.

Effect of race on outcome of white and black children with acute myeloid leukemia: the St. Jude experience.

Rubnitz JE, Lensing S, Razzouk BI, Pounds S, Pui CH, Ribeiro RC.

Pediatr Blood Cancer. 2007 Jan;48(1):10-5.

PMID:
16642489
15.

Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group.

Children's Oncology Group, Aplenc R, Alonzo TA, Gerbing RB, Smith FO, Meshinchi S, Ross JA, Perentesis J, Woods WG, Lange BJ, Davies SM.

Blood. 2006 Jul 1;108(1):74-80. Epub 2006 Mar 14.

16.

Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.

Bagatell R, Rumcheva P, London WB, Cohn SL, Look AT, Brodeur GM, Frantz C, Joshi V, Thorner P, Rao PV, Castleberry R, Bowman LC.

J Clin Oncol. 2005 Dec 1;23(34):8819-27.

PMID:
16314642
17.

Integrative epidemiology: from risk assessment to outcome prediction.

Spitz MR, Wu X, Mills G.

J Clin Oncol. 2005 Jan 10;23(2):267-75. Review.

PMID:
15637390
18.

Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia.

Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG.

JAMA. 2003 Oct 15;290(15):2008-14.

PMID:
14559954
19.

Racial and ethnic differences in survival of children with acute lymphoblastic leukemia.

Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynon PS, Robison LL.

Blood. 2002 Sep 15;100(6):1957-64.

20.

Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.

Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Perez C, Haase GM, Matthay KK.

J Clin Oncol. 2000 Mar;18(6):1260-8.

PMID:
10715296

Supplemental Content

Support Center